Last reviewed · How we verify
NCT06840717: SNP
Association Between Genetic Polymorphisms and Type 2 Asthma in Children
trial in Asthma in Children in 300 participants. Currently enrolling.
30 December 2025
Quick facts
| Lead sponsor | Guangzhou Institute of Respiratory Disease |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 30 January 2024 |
| Primary completion | 30 December 2025 |
| Estimated completion | 30 December 2025 |
| Sites | 1 location across China |
Conditions studied
- Asthma in Children — all drugs for Asthma in Children →
- Genetic Disease — all drugs for Genetic Disease →
- Inflammation — all drugs for Inflammation →
Sponsor
Guangzhou Institute of Respiratory Disease
Who can join
Adults 3 to 14, any sex, with Asthma in Children or Genetic Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To further understand the role of gene single nucleotide polymorphism (SNP) in the occurrence of type 2 inflammation-related asthma in children by analyzing the gene single nucleotide polymorphism (SNP), lung function and type 2 inflammation indicators of children diagnosed with asthma in outpatient and inpatient. To provide a theoretical basis for the study of personalized treatment and prevention strategies for asthma.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06840717
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Asthma in Children
Currently open trials in the same condition.
- NCT06372249 — A Clinical Trial of Soluble Fiber for Asthma · Phase 2 · recruiting
- NCT07412769 — ASMact: Study on Management of Bronchial Asthma · recruiting
- NCT07138027 — SMART Implementation-Effectiveness Trial 2 · NA · recruiting
- NCT07137923 — SMART Implementation-Effectiveness Trial 1 · NA · recruiting
- NCT06851715 — Improving Quality of Life for Teenagers With Asthma · NA · recruiting
Other Guangzhou Institute of Respiratory Disease trials
Trials by the same sponsor.
- NCT07092137 — Nano-crystalline Megestrol Acetate for Anorexia-Cachexia Syndrome in Advanced Lung Cancer · Phase 2 · not yet recruiting
- NCT06909383 — Nanocrystalline Megestrol Acetate for the Treatment of Anorexia-Cachexia Syndrome in Extensive-Stage Small Cell Lung Can · Phase 2 · not yet recruiting
- NCT07005999 — Interventional Ablation for Early-stage Lung Cancer · active not recruiting
- NCT06739928 — Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC · Phase 2 · recruiting
- NCT06715956 — Observational Study of Sputum Inflammation Phenotypes and Clinical Outcomes in Non-Cystic Fibrosis Bronchiectasis · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06840717 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Guangzhou Institute of Respiratory Disease
- Last refreshed: 21 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06840717.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing